Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 145 Publications

21 Customer Reviews

  • Indisulam dependent degradation of RBM39 can be blocked by bortezomib, a proteasome inhibitor. Cells were pretreated with indicated concentrations of bortezomib for 2 hours, followed by 6 hours of treatment with 2 μM indisulam. The effect of bortezomib is attenuated in a bortezomib resistant cell line.

    Science, 2017, eaal3755. Bortezomib (PS-341) purchased from Selleck.

    Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

  • Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

  • Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

    Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

  • Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

    Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

  • (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

    Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

     

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

  • Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 M{XVfmN6fG:2b4jpZ{BCe3OjeR?= NVvRVVJoPTBizszN NWO5dWxlPDhiaB?= NHvq[5hFVVOR Mmq3T4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> Mn;tNVA1QTl4NEO=
OVCA 429 MVXGeY5kfGmxbjDBd5NigQ>? M17FW|MxOCCwTR?= MljNOFghcA>? MXLEUXNQ NV71TIVtTGm|coXweJMhcW62YXP0JI12dHSrY3XscJVt[XJidIXtc5Ihe3CqZYLvbYR{ NX\6SVc{OTB7OUm3OlY>
RPMI8226 M37IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGxNFAhdk1? NFLqWZc1QCCq NFLKSnVFVVOR MWnJR|UxRTNyIH7N M1z2UFEyOzB4NEi5
Dox40 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDu[GgyODBibl2= NEjNPIE1QCCq NHLUW5pFVVOR M3fMRmlEPTB;NECgcm0> NVL2XJVZOTF|ME[0PFk>
MR20 NG[4Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PjWVExOCCwTR?= NEP5WXU1QCCq NEn0N25FVVOR MljXTWM2OD1{MDDuUS=> MoH6NVE{ODZ2OEm=
LR5 M2nBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;uNVAxKG6P NF73Xoo1QCCq M13OTWROW09? NW\uVZpxUUN3ME2yNEBvVQ>? MYGxNVMxPjR6OR?=
U266 NGW5TnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nJNFExOCCwTR?= M4XkblQ5KGh? MmDUSG1UVw>? NV3VV20yUUN3ME2zJI5O NFu0VnEyOTNyNkS4PS=>
IM-9 M2PFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEThd2QyODBibl2= NHzGVVI1QCCq M2i4NGROW09? NV;CWVIyUUN3ME22JI5O Ml7uNVE{ODZ2OEm=
Hs Sultan NFjCWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVSxNFAhdk1? M16wdFQ5KGh? NGOzXW9FVVOR NW\tVmN6UUN3ME2yNEBvVQ>? MX2xNVMxPjR6OR?=
PAM-LY2 NY\jeI04TnWwY4Tpc44hSXO|YYm= NYrrcnF3OTByIH7N MYixNkBp M3LHVmROW09? NYHKS|c6UW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44> MkHLNVE{PTB7MUO=
PAM 212 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnGzNVAxKG6P MU[3NkBp NEDJcZlFVVOR MkHiTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MU[xNVM2ODlzMx?=
PAM-LY2 NUW5WnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPt[o0yODBibl2= MV:3NkBp NFvSVYZFVVOR M2jafmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NYTiXnI1OTF|NUC5NVM>
B4B8 M3;YN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\mNVAxKG6P NITncoU4OiCq NI[0VoZFVVOR M3XUcmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MnLzNVE{PTB7MUO=
B7E3 NFnHbnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrTZ5A3OTByIH7N MWm3NkBp NIC3[GxFVVOR MVXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MnfqNVE{PTB7MUO=
UM-SCC-9 M{TLeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj6S2t3OTByIH7N NVf4OJI{PzJiaB?= NEjTNHFFVVOR MYXJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M3z5b|EyOzVyOUGz
UM-SCC-11B MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXzNVAxKG6P NUXXNXZlPzJiaB?= M1iwc2ROW09? MnjaTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? NXfGeVB5OTF|NUC5NVM>
H460 MoTYSpVv[3Srb36gRZN{[Xl? NH3FXmcyOCEQvF2= NHLkWGUzPCCq M1\kcGROW09? NHvoUolKdmS3Y3XzJGJkdC1{IIDoc5NxcG:{eXzheIlwdiCjbnSgZ4xm[X[jZ3WgZ49zemWuYYTl[EB4cXSqIFeyMW0heGijc3WgZZJz\XO2 MofyNVI1QTJzMUe=
U266 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rzN|UxOCCwZz;tcC=> MUi0PEBp NGC0dpZFVVOR NXjONHZVUW6qaXLpeJMh[2WubDDndo94fGh? MUmxNlY{OTZzOR?=
ARH77 MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzaO3hOPTByIH7nM41t NYPuTIlZPDhiaB?= MojLSG1UVw>? NIfmWWRKdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mm[4NVI3OzF4MUm=
WAD-1 NI\mfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjnTI1jPTByIH7nM41t NWexR4w2PDhiaB?= M4DrTWROW09? M3H1RWlvcGmkaYTzJINmdGxiZ4Lve5Rp NUj0V2IzOTJ4M{G2NVk>
U266/LR7 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfDOVAxKG6pL33s NULWOoFyPDhiaB?= MUfEUXNQ NYLze3ZMUW6qaXLpeJMh[2WubDDndo94fGh? M{m5UVEzPjNzNkG5
U266/dox4 M4THUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:1NFAhdmdxbXy= MkPpOFghcA>? NYrRV4FKTE2VTx?= NF7tdVRKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NGnCSY0yOjZ|MU[xPS=>
RPMI8226/LR5 M3znWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHftd5I2ODBibnevcYw> MVy0PEBp NXL0UZhXTE2VTx?= Ml73TY5pcWKrdIOgZ4VtdCCpcn;3eIg> MmDNNVI3OzF4MUm=
H460 M{HjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNEDPxE1? MmjHO|IhcA>? NYHXUJV[TE2VTx?= NWHqXWpQUUN3ME2xNFAhdk1? NHH6Tm4yOjZ|MU[yNC=>
H358 M{ToWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXuxNEDPxE1? NVO3NG1ZPzJiaB?= M2LPXmROW09? MmTZTWM2OD15MDDuUS=> M3SzSFEzPjNzNkKw
H322 Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixNEDPxE1? M2LpZlczKGh? MmnzSG1UVw>? M{PnbmlEPTB;NkKwJI5O NVzyWHhKOTJ4M{G2NlA>
H460 MWnGeY5kfGmxbjDBd5NigQ>? M4fadlExOCCwTR?= M2jibVI1KGh? MnTkSG1UVw>? M3nJ[Glv\HWlZYOgS|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO|ZX3icJku\Gm|YYPz[Y1jdHl? M2CyR|EzPjNzNkKw
LNCap-Pro5 MULGeY5kfGmxbjDBd5NigQ>? MUKxJO69VQ>? MlnHOEBp M4n3[2ROW09? NUDYT4hwW3SjYnnsbZpmeyCyNUO= MV[xOFYyOjV|Mh?=
T29 M3K5c2Fxd3C2b4Ppd{BCe3OjeR?= M4XGO|UxKG6P NFnjfXg1QCCqIB?= MVvEUXNQ MnroTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NWfTR5VNOTZ5N{ixO|k>
T29Kt1 MYfBdI9xfG:|aYOgRZN{[Xl? MnXEOVAhdk1? NEThXlA1QCCqIB?= NV7COYh5TE2VTx?= Mme5TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1m3elE3Pzd6MUe5
HCT116 NWDkXlZvSXCxcITvd4l{KEG|c3H5 MkftOVAhdk1? MmC4OFghcCB? MV;EUXNQ MVTJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NHHiXVcyPjd5OEG3PS=>
HKe-3 MYnBdI9xfG:|aYOgRZN{[Xl? MYq1NEBvVQ>? M2LuNlQ5KGhi MlLKSG1UVw>? NFjrNXlKdmS3Y3XzJINmdGxiYYDvdJRwe2m| MWKxOlc4QDF5OR?=
NB-1691 M2q4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmxJO69VQ>? NITFNpY4OiCq MlHHTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDVn M2jRZ|E4Pjh7Nki0
CHLA-255 NGnTbIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xJO69VQ>? NET4dYc4OiCq MX3Jcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV? MYCxO|Y5QTZ6NB?=
SK-N-AS NWPHTWc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;MNUDPxE1? M4fTWVczKGh? Ml;rTY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJJRwKDFyJR?= NH\1TFkyPzZ6OU[4OC=>
NB-1691 Ml;DSpVv[3Srb36gRZN{[Xl? NFnPS3AyOCCwTR?= M1LWXlI1KGh? M3zpSHNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NIDSSI0yPzZ6OU[4OC=>
CHLA-255 M37Q[mZ2dmO2aX;uJGF{e2G7 M3\Me|ExKG6P M1;ITVI1KGh? NIPoelFOd2Snc4TsfUBz\WS3Y3XzJINmdGy|IHnuJJRp\SCJMD;HNUBxcGG|ZR?= MmjlNVc3QDl4OES=
RPMI 8226 M4DyRWZ2dmO2aX;uJGF{e2G7 NF7w[3QzOCCwTR?= MUG4JIg> NIXEUmFUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MYGxPVQ{PjB3MB?=
MM.1S NFTY[HFHfW6ldHnvckBCe3OjeR?= NIrWOmczOCCwTR?= MkS4PEBp MV;TbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> NFTTOY4yQTR|NkC1NC=>
U266 M1\Td2Z2dmO2aX;uJGF{e2G7 M2nIdVIxKG6P NHTvdpg5KGh? NEnoZYdUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? Mm[wNVk1OzZyNUC=
OPM1 NXvZN4UyTnWwY4Tpc44hSXO|YYm= MVuyNEBvVQ>? M4TJTFghcA>? NHfqeJNUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? MoHyNVk1OzZyNUC=
INA6 NVjNcpQ3TnWwY4Tpc44hSXO|YYm= MWSyNEBvVQ>? NIrqNFU5KGh? NXvsZYRsW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NHLLNo4yQTR|NkC1NC=>
OPM2 NIHQdZRHfW6ldHnvckBCe3OjeR?= NH\n[FkzOCCwTR?= NFPEdII5KGh? MXzTbYdvcW[rY3HueIx6KGWwaHHuZ4V{KE6ILd86RkBi[3Srdnn0fS=> MkPYNVk1OzZyNUC=
RPMI 8226 MljySpVv[3Srb36gRZN{[Xl? MmXBNlAhdk1? MlPHPEBp MUjJcoR2[2W|IFTORUB{gW62aHXzbZM> MVGxPVQ{PjB3MB?=
BaF/3 M4XCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK3NVAxKG6P MnPzOFghcA>? MV7JR|UxRTZwMjDuUS=> MlS2NlA{ODV4OUK=
BaF/3-p210 NVThWnQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjw[FdsOTByIH7N MnqwOFghcA>? NVnCWGRUUUN3ME20Mlchdk1? MXGyNFMxPTZ7Mh?=
TCC-S NYSyVIQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXWxNFAhdk1? MYm0PEBp NFHmb2JKSzVyPUKuPEBvVQ>? NHTCSFIzODNyNU[5Ni=>
BaF/3 M{HIe2Z2dmO2aX;uJGF{e2G7 NY\mTHNPPiCwTR?= NHHR[5c1QCCq NHjteYNKdmS3Y3XzJIEh\3KnYYSgS|Eh[2WubD3jfYNt\SCjcoLld5Q> M2fnUlIxOzB3Nkmy
BaF/3-p210 MYHGeY5kfGmxbjDBd5NigQ>? M4Pad|Yhdk1? MmDROFghcA>? NGrXfplKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 M4\0[lIxOzB3Nkmy
BaF/3-p210 MoKwSpVv[3Srb36gRZN{[Xl? NV\DNZpSPiCwTR?= MmS0NlQhcA>? MXfS[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gZY5lKHSqZTDhZ5Rqfmm2eTDv[kBT[g>? NH63XXczODNyNU[5Ni=>
Raji M3Lre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvFSmYyKM7:TR?= NF\NfZkzPCCq NX\u[W9ZWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXmyNVE4ODl6OB?=
LCL-1 M2jYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxJO69VQ>? NEOyTFUzPCCq MnvCVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NYjlcXJpOjFzN{C5PFg>
LCL-2 M4HkO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1e5NFEh|ryP NGPx[5IzPCCq M3LkOnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= MnzQNlEyPzB7OEi=
BJAB MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHn5PFgyKM7:TR?= M2nE[lI1KGh? MnvuVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi M2XKR|IyOTdyOUi4
SNT-13 NYHrTm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHONUDPxE1? MWCyOEBp NHX2N2FT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MnPJNlEyPzB7OEi=
SNT-16 Mn3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSxJO69VQ>? MnHHNlQhcA>? MVPS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? NET5cIkzOTF5MEm4PC=>
Jurkat NGCxVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUWxJO69VQ>? MlntNlQhcA>? NXrRSm42WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXeyNVE4ODl6OB?=
KAI-3 NGjiWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vYRVEh|ryP MXSyOEBp NUT4VXF3WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NHm3TokzOTF5MEm4PC=>
SNK-6 M1fOTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFS0eooyKM7:TR?= NEi3N5IzPCCq NGXQeWFT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= NGTQeJEzOTF5MEm4PC=>
KHYG-1 NVrzbZBrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Ho[VEh|ryP NYHOdGRWOjRiaB?= NFXOZ|lT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MkD3NlEyPzB7OEi=
SNT-16 NUn0V2EzSXCxcITvd4l{KEG|c3H5 NH7ZRlUyKM7:TR?= NID2elQ3KGh? MlLTTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NHrJT3kzOTF5MEm4PC=>
Jurkat M1vWdGFxd3C2b4Ppd{BCe3OjeR?= MVuxJO69VQ>? MU[2JIg> M32zNWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MWKyNVE4ODl6OB?=
KAI-3 MVvBdI9xfG:|aYOgRZN{[Xl? M2HJbVEh|ryP NFftO2Q3KGh? M3XPe2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NGm5OpEzOTF5MEm4PC=>
KHYG-1 MVjBdI9xfG:|aYOgRZN{[Xl? MljJNUDPxE1? NVrQVHc4PiCq M4HmVGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NEjFfpMzOTF5MEm4PC=>
SNT-13 MoXIRY51cX[rcnHsJGF{e2G7 NUTS[YxuOSEQvF2= NI\pTIwzPCCq NXfJSGh3UW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY NUe2OZZLOjFzN{C5PFg>
SNT-16 NX3TVZo5SW62aY\pdoFtKEG|c3H5 NYW1dmtIOSEQvF2= NHjISVQzPCCq MUHJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> M1\aeFIyOTdyOUi4
KAI-3 MVXBcpRqfmm{YXygRZN{[Xl? NX3rN|dpOSEQvF2= MYSyOEBp Mn7MTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX NFK4W3AzOTF5MEm4PC=>
SNK-6 M1rvcGFvfGm4aYLhcEBCe3OjeR?= NEPUWmwyKM7:TR?= NHvXdI0zPCCq NHrSSXBKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? Ml7ZNlEyPzB7OEi=
RAW 264.7 MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfN[XgyODBibl2= MYW0PEBp MYDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? Mn;kNlI1OjdzNUS=
A375 MnrQRZBweHSxc3nzJGF{e2G7 MYKxNEBvVQ>? NEWwWlUzPCCq MYfJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NYC3S4FROjNyN{mwPFM>
BLM NH3pOHJCeG:ydH;zbZMhSXO|YYm= NYDpRmduOTBibl2= MlfaNlQhcA>? M2XmR2lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MUiyN|A4QTB6Mx?=
A375 MnzaRZV1d3CqYXf5JGF{e2G7 NYLYc2dROTBibl2= NWTTOFFjOTJiaB?= NX\o[4txUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> MX6yN|A4QTB6Mx?=
BLM MY\BeZRweGijZ4mgRZN{[Xl? M2\NWlExKG6P MkL0NVIhcA>? M2XjXGlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXz NGnDV4YzOzB5OUC4Ny=>
H1299 NEXQUlFCeG:ydH;zbZMhSXO|YYm= MXq4NEBvVQ>? MW[yOEBp NUmzXIhRTE2VTx?= MV7T[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? MUCyOVMzOzZ7Mx?=
Hut-78 MYTGeY5kfGmxbjDBd5NigQ>? MYSxNFAhdk1? MVGyOEBp NI\4OlVFVVOR Mk\ySI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w NXnHZ4J3OjV4OEGzN|U>
H9 NHi5R41HfW6ldHnvckBCe3OjeR?= MVixNFAhdk1? NYfYUYJwOjRiaB?= M{XVeGROW09? MorTSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOSCneIDy[ZN{cW:w MXiyOVY5OTN|NR?=
HH Mn;iSpVv[3Srb36gRZN{[Xl? NVXzU5piOTByIH7N NGHkS4wzPCCq NEDQRVhFVVOR NYfq[HBv\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u MXiyOVY5OTN|NR?=
Hut-78 MmXYUYloemG2aX;uJGF{e2G7 NIXEVZcyODBibl2= NFfnWJgzPCCq NV;zdGl7TE2VTx?= M{DzZnJm\HWlZYOgZ4VtdCCvaXfyZZRqd25iYomgPFDjiJN7MDW= MYKyOVY5OTN|NR?=
HH MVXNbYdz[XSrb36gRZN{[Xl? NXezT5Y{OTByIH7N Ml\JNlQhcA>? NF3YflNFVVOR NF\JVYRT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUGl MW[yOVY5OTN|NR?=
U937 NXjYeJRlTnWwY4Tpc44hSXO|YYm= NFXjRpEyODBibl2= Ml7hOkBp Ml\KTY5lfWOnczDJUE05KGW6cILld5Nqd25iaX6gUHBUNXO2aX31cIF1\WRiVUmzO{Bu[WO{b4DoZYdmew>? M3LMe|I2PzlzNEe3
human PBMC NWn0OFFzTnWwY4Tpc44hSXO|YYm= MkDWNVAxKG6P MoS2NlQhcA>? Ml\qTY5lfWOnczDJUE05KHKnbHXhd4U> M1XZ[|I2PzlzNEe3
ES6 NHH3XHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3vZVhiUUN3ME2wMlAxOjFibl2= NY\LPWJsW0GQR1XS
SK-UT-1 M1vtb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELhTWtKSzVyPUCuNVY{KG6P M2fUO3NCVkeHUh?=
SH-4 NXrkSo9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTBwMUezJI5O NFPOS5FUSU6JRWK=
TE-9 Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn4TWM2OD1yLkG4NkBvVQ>? Mnn4V2FPT0WU
A253 NIXXTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e3W2lEPTB;MD6yNFghdk1? NWXtSWV5W0GQR1XS
no-10 M1nsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDJOo41UUN3ME2wMlIyKG6P MWfTRW5ITVJ?
MMAC-SF NGnvbm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITkOpVKSzVyPUCuNlE3KG6P MmHnV2FPT0WU
A101D MnW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\EU2lEPTB;MD6yNlUhdk1? MlLBV2FPT0WU
NTERA-S-cl-D1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMkSzJI5O MU\TRW5ITVJ?
8-MG-BA M2njbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{WwemlEPTB;MD6yOUBvVQ>? MX7TRW5ITVJ?
KNS-42 NGLZdYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPPV5lKSzVyPUCuNlU5KG6P M1HCTHNCVkeHUh?=
LXF-289 NITuU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrXbYtKSzVyPUCuNlY6KG6P MVfTRW5ITVJ?
OVCAR-4 NFLhfZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\3U2lSUUN3ME2wMlI5QSCwTR?= NGXZcoRUSU6JRWK=
LOUCY MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMkmzJI5O M1PKUHNCVkeHUh?=
BB65-RCC M3TUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\HTWM2OD1yLkOwOEBvVQ>? M4L1WXNCVkeHUh?=
D-542MG M2G5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwM{K5JI5O MmH2V2FPT0WU
ONS-76 NF7tNIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7UTWM2OD1yLkOzJI5O MY\TRW5ITVJ?
BB30-HNC NE\XdZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Huc2lEPTB;MD6zN|Uhdk1? MY\TRW5ITVJ?
KS-1 NUPmSm9KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwM{Sgcm0> NHOwcZBUSU6JRWK=
A388 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq3SlhnUUN3ME2wMlM2PiCwTR?= NYm1S4RiW0GQR1XS
ES8 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nYT2lEPTB;MD60JI5O M2jYe3NCVkeHUh?=
MZ2-MEL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnv[ok3UUN3ME2wMlQxPyCwTR?= M1\CS3NCVkeHUh?=
HCC2998 NV3ZOHV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT2bINKSzVyPUCuOFEzKG6P NGPXcmpUSU6JRWK=
D-247MG NHTocYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7xTWM2OD1yLkSxN{BvVQ>? NXHWZ21{W0GQR1XS
ACN NGrMTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTOOpRYUUN3ME2wMlQyPyCwTR?= NWC1cVZyW0GQR1XS
LB2518-MEL NFXZTW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfRfYNKSzVyPUCuOFI2KG6P MY\TRW5ITVJ?
ES1 NVrIOIZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNEOgcm0> NWjvUYdTW0GQR1XS
HCE-T NYnzUZdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwNEO5JI5O M4XwT3NCVkeHUh?=
OS-RC-2 MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHpbYZKSzVyPUCuOFQhdk1? NI[3WI5USU6JRWK=
MFH-ino NHzUeZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfiTWM2OD1yLkS0N{BvVQ>? M3rIbXNCVkeHUh?=
OCUB-M NFjRRnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNES3JI5O MlS1V2FPT0WU
CP66-MEL NXrJWY1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi1TWM2OD1yLkS3N{BvVQ>? M3vZPHNCVkeHUh?=
LB771-HNC NEDjUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\TZmlEPTB;MD60O|Qhdk1? MkX0V2FPT0WU
DSH1 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PPTWlEPTB;MD60PEBvVQ>? NIrZ[2RUSU6JRWK=
HUTU-80 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjkV29KSzVyPUCuOVM{KG6P NGXy[JFUSU6JRWK=
CESS M4G0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwNUO4JI5O MYjTRW5ITVJ?
NCI-H747 MoH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm1[4tKSzVyPUCuOVM6KG6P M3HYNHNCVkeHUh?=
HT-144 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofpTWM2OD1yLkW3OkBvVQ>? MVXTRW5ITVJ?
COLO-829 NFHBSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTheHRQUUN3ME2wMlYyPCCwTR?= MVHTRW5ITVJ?
A4-Fuk M3fw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPMU24yUUN3ME2wMlYzOyCwTR?= NEfFXoxUSU6JRWK=
GI-ME-N NWfx[Iw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL1TWM2OD1yLk[zOEBvVQ>? MkH0V2FPT0WU
LB831-BLC M3vG[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmyT4YxUUN3ME2wMlY1OSCwTR?= NGXaN3ZUSU6JRWK=
HOP-62 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf2b4NKSzVyPUCuOlQ4KG6P NHnyd3hUSU6JRWK=
BB49-HNC MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNkWyJI5O M130XnNCVkeHUh?=
D-336MG Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnm[JlKSzVyPUCuOlU4KG6P MkWwV2FPT0WU
TK10 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITLeIVKSzVyPUCuOlc6KG6P M2TOTHNCVkeHUh?=
Ramos-2G6-4C10 NETlZ5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7SfXR2UUN3ME2wMlY6OyCwTR?= NYLQVG5kW0GQR1XS
LB373-MEL-D MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzL[GpKSzVyPUCuO{BvVQ>? NUnEe|ZzW0GQR1XS
SF126 NFHQSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\pV2lEPTB;MD63NFEhdk1? Mm\NV2FPT0WU
UACC-257 M3;ZNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDhTWlKSzVyPUCuO|Ehdk1? NX\ZXFBIW0GQR1XS
KINGS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTJTWM2OD1yLkeyNkBvVQ>? MlzIV2FPT0WU
LS-513 NWTuO|VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwN{O5JI5O NXzzUJZHW0GQR1XS
GI-1 M4[4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j4UGlEPTB;MD63OlQhdk1? NG\WZWRUSU6JRWK=
ES7 NEDYRnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwN{[2JI5O MX\TRW5ITVJ?
LB2241-RCC NWGyToZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qzV2lEPTB;MD64NFQhdk1? MYTTRW5ITVJ?
D-263MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3T5RmlEPTB;MD64NFchdk1? MkPaV2FPT0WU
SW684 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DYT2lEPTB;MD64NlEhdk1? NVWxS2Q{W0GQR1XS
ML-2 NX2zdFJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TKTmlEPTB;MD64NlEhdk1? MVzTRW5ITVJ?
SK-LMS-1 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XlZWlEPTB;MD64OVQhdk1? NYjiPGxOW0GQR1XS
TE-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDUeGxsUUN3ME2wMlg3PSCwTR?= NIDFVXJUSU6JRWK=
QIMR-WIL NW\tbmhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nwbWlEPTB;MD64PFkhdk1? MU\TRW5ITVJ?
NCI-H1355 M3HqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nCOmlEPTB;MD64PVUhdk1? NVj0[ZN3W0GQR1XS
SNB75 M13kOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwOUGyJI5O Moi0V2FPT0WU
RXF393 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwOUG0JI5O NYTP[G5QW0GQR1XS
IST-MEL1 M{juPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwOUG3JI5O Ml2zV2FPT0WU
SF268 M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33YTmlEPTB;MD65NlMhdk1? MmTZV2FPT0WU
KALS-1 Mm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PqZWlEPTB;MD65NlUhdk1? M4rmfHNCVkeHUh?=
HC-1 NXjIOXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOUe1JI5O MW\TRW5ITVJ?
SW872 NV\xUYNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHSd29JUUN3ME2wMlk6PiCwTR?= Mn3VV2FPT0WU
PSN1 NH7rWWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXuwOJJ{UUN3ME2xMlAyKG6P M{nmbHNCVkeHUh?=
TE-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LNN2lEPTB;MT6wN{BvVQ>? MlPRV2FPT0WU
TE-10 NVXMO29iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwMEOgcm0> NEDRO3JUSU6JRWK=
RKO MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmD2TWM2OD1zLkC2JI5O NX;aNJp7W0GQR1XS
LC-2-ad MnvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XpSWlEPTB;MT6wPEBvVQ>? NIGyTGpUSU6JRWK=
SK-MM-2 M3PFe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDETWM2OD1zLkC5JI5O M3:2eHNCVkeHUh?=
VA-ES-BJ MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLVTWM2OD1zLkC5JI5O MmLWV2FPT0WU
MZ7-mel NHXWRpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMEmgcm0> NFi4ZW9USU6JRWK=
D-392MG MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHzTWM2OD1zLkGgcm0> MWnTRW5ITVJ?
CCRF-CEM Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jEeGlEPTB;MT6xN{BvVQ>? M3K0NnNCVkeHUh?=
EM-2 M3i4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHHTWM2OD1zLkG2JI5O Ml[5V2FPT0WU
HAL-01 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz2TWM2OD1zLkG4JI5O NIfhblBUSU6JRWK=
TE-8 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDlTWM2OD1zLkG5JI5O MkDLV2FPT0WU
NCI-H1882 NVy3SnVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{j1XGlEPTB;MT6yJI5O NYPROphvW0GQR1XS
Daudi NGrQSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT6TnFOUUN3ME2xMlIzKG6P MkLzV2FPT0WU
BL-41 NXXDN5VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfjVXJJUUN3ME2xMlI2KG6P NFjxdnpUSU6JRWK=
SR NEP5OmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnaN5g4UUN3ME2xMlI2KG6P MX7TRW5ITVJ?
KM12 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELzZ2hKSzVyPUGuNlchdk1? M3z6V3NCVkeHUh?=
K5 M1rLe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETTdHpKSzVyPUGuNlghdk1? M{DiWXNCVkeHUh?=
A3-KAW Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYn0ZYFYUUN3ME2xMlI5KG6P Mly2V2FPT0WU
CMK M1rt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vQW2lEPTB;MT6yPUBvVQ>? NIm1d4dUSU6JRWK=
Calu-6 NUHnbHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;I[mlEPTB;MT6yPUBvVQ>? NGrScmVUSU6JRWK=
IST-SL2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULRdYlWUUN3ME2xMlMyKG6P MmPBV2FPT0WU
OPM-2 MnnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTFwM{Ogcm0> MXHTRW5ITVJ?
DU-4475 Ml7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwM{[gcm0> MU\TRW5ITVJ?
ECC12 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fTbmlEPTB;MT6zO{BvVQ>? NX:wbWRSW0GQR1XS
L-540 NGHKUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0SmlEPTB;MT6zO{BvVQ>? MY\TRW5ITVJ?
CAS-1 NXfpbmxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwM{egcm0> M{O3WHNCVkeHUh?=
PF-382 M4rqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTWW25oUUN3ME2xMlQ4KG6P Mn7OV2FPT0WU
LS-411N M{f1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH4TZZKSzVyPUGuOVMhdk1? MYTTRW5ITVJ?
NCI-H69 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzrSYxiUUN3ME2xMlU1KG6P NVjEOI1KW0GQR1XS
NB12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwNU[gcm0> MY\TRW5ITVJ?
HEL M4\LUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvRNoJKSzVyPUGuOlEhdk1? MXfTRW5ITVJ?
GCIY NXjrZVdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmiyTWM2OD1zLk[yJI5O NV[xclZqW0GQR1XS
EHEB MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwNkegcm0> Ml7vV2FPT0WU
TGBC1TKB M3;pfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPFWlhKSzVyPUGuO|Ehdk1? M4DwV3NCVkeHUh?=
KURAMOCHI MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m5TmlEPTB;MT63NkBvVQ>? M4fHWHNCVkeHUh?=
U-266 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\CUGlEPTB;MT63OkBvVQ>? MnfDV2FPT0WU
LC4-1 NHHX[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDKU|JVUUN3ME2xMlc6KG6P NUS2Wm14W0GQR1XS
NCI-H2126 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD1zLkigcm0> M1S1XnNCVkeHUh?=
NCI-H1092 NVzrWldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwODDuUS=> NEH3Om1USU6JRWK=
GB-1 MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\a[JR7UUN3ME2xMlgyKG6P MnryV2FPT0WU
MV-4-11 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLjTWM2OD1zLkiyJI5O NGXPeGVUSU6JRWK=
Becker MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTlTWM2OD1zLkizJI5O NFP3dFZUSU6JRWK=
MPP-89 MnnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwOEmgcm0> MXHTRW5ITVJ?
BE-13 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjXWY57UUN3ME2xMlk{KG6P NVLPU4lNW0GQR1XS
697 NH:yb5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXaTWM2OD1zLkm5JI5O NFrsTm9USU6JRWK=
NKM-1 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsXGlEPTB;MjDuUS=> NFHQN|NUSU6JRWK=
NB13 M1Ho[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTJibl2= NIK0ZWpUSU6JRWK=
LS-123 M3\iNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;tcVRKSzVyPUKuNFIhdk1? M4XWfXNCVkeHUh?=
NB17 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPj[nZKSzVyPUKuNFQhdk1? NIDieFlUSU6JRWK=
LAN-6 NWTpTZNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\TTWM2OD1{LkC1JI5O MWXTRW5ITVJ?
EW-24 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;D[mlEPTB;Mj6wPEBvVQ>? NVT0[ZFmW0GQR1XS
NOS-1 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnDRXJvUUN3ME2yMlEyKG6P MnGxV2FPT0WU
BL-70 NWO0cZhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmyenlKSzVyPUKuNVIhdk1? MmPHV2FPT0WU
GT3TKB NWjvdXVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPKTWM2OD1{LkGyJI5O MofMV2FPT0WU
HH MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfWfYpEUUN3ME2yMlE{KG6P MkmwV2FPT0WU
KE-37 NEjVcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJwMUOgcm0> M{PDVXNCVkeHUh?=
MOLT-4 NHPST|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwMUOgcm0> NV\EcYpSW0GQR1XS
EKVX MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTJwMUSgcm0> M2jJZXNCVkeHUh?=
KGN NYfI[Zd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3PTWM2OD1{LkG1JI5O MVTTRW5ITVJ?
ES4 M3XZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\zTWM2OD1{LkG2JI5O M4[2NnNCVkeHUh?=
SJSA-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Pb|ROUUN3ME2yMlIyKG6P NEOyeVZUSU6JRWK=
KMOE-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYizW5d7UUN3ME2yMlI{KG6P NEO1foZUSU6JRWK=
NB5 NUPybYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Txd2lEPTB;Mj6yO{BvVQ>? NYLSbpdOW0GQR1XS
BC-1 M2\NeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHNTWM2OD1{LkOxJI5O M4fjNnNCVkeHUh?=
NB10 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTlN4FKSzVyPUKuN|Ihdk1? MmjPV2FPT0WU
RPMI-8226 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTJwM{Wgcm0> MYXTRW5ITVJ?
SCC-3 NUnVNG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sOlJKSzVyPUKuN|chdk1? NYjkT49zW0GQR1XS
ARH-77 M2rzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF61e2JKSzVyPUKuN|ghdk1? MnLPV2FPT0WU
NCI-H748 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfweZdKSzVyPUKuN|khdk1? NXnER2pxW0GQR1XS
KU812 M1PqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fpb2lEPTB;Mj60NkBvVQ>? NHTFOnBUSU6JRWK=
NCI-H64 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3yyeWlEPTB;Mj60OEBvVQ>? MUDTRW5ITVJ?
NB69 M1rmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fXRmlEPTB;Mj60OkBvVQ>? NIPObYJUSU6JRWK=
KNS-81-FD NEf6W|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7tbGlQUUN3ME2yMlQ5KG6P MlqzV2FPT0WU
LB1047-RCC NX7CWZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13VWWlEPTB;Mj61O{BvVQ>? MorxV2FPT0WU
EB-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M361N2lEPTB;Mj62OkBvVQ>? Mn7RV2FPT0WU
Mo-T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nhO2lEPTB;Mj63OEBvVQ>? MWXTRW5ITVJ?
EW-16 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnOTWM2OD1{Lke1JI5O NEPidJNUSU6JRWK=
CTV-1 NG\DSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkCwTWM2OD1{Lkigcm0> MX;TRW5ITVJ?
ETK-1 NITlW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rCNmlEPTB;Mj64OEBvVQ>? MUnTRW5ITVJ?
C2BBe1 NIH2cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwOEmgcm0> M2j5U3NCVkeHUh?=
MOLT-16 MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwOEmgcm0> Mm[5V2FPT0WU
SW954 M4P1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjVbnFTUUN3ME2yMlkhdk1? MXPTRW5ITVJ?
HT MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rnfWlEPTB;Mz6wNkBvVQ>? NWKzWpppW0GQR1XS
KARPAS-299 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTNwME[gcm0> MV\TRW5ITVJ?
MONO-MAC-6 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF34NFhKSzVyPUOuNUBvVQ>? M2jMOXNCVkeHUh?=
CGTH-W-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfWNIhKSzVyPUOuNUBvVQ>? MVrTRW5ITVJ?
SK-PN-DW NED0[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfHcmVKSzVyPUOuNVQhdk1? Mk[1V2FPT0WU
CW-2 NFnDbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHZRZFKSzVyPUOuNlEhdk1? M{PNNnNCVkeHUh?=
SK-N-DZ NIfWdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPtTWM2OD1|LkK2JI5O M{nBO3NCVkeHUh?=
NEC8 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTpSHIxUUN3ME2zMlM2KG6P NWjBSYRkW0GQR1XS
LB996-RCC MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnqTWM2OD1|LkSgcm0> MXrTRW5ITVJ?
DB NGPqVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPoW|lKSzVyPUOuOFEhdk1? MY\TRW5ITVJ?
TE-15 M4qxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnywTWM2OD1|LkSzJI5O MX;TRW5ITVJ?
COR-L88 NH65T25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r3bGlEPTB;Mz60O{BvVQ>? NE\Fd2VUSU6JRWK=
LAMA-84 NXK3WWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\VRYZKSzVyPUOuOFkhdk1? MYHTRW5ITVJ?
MEG-01 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPzTWM2OD1|LkS5JI5O NVWzNVRxW0GQR1XS
LOXIMVI MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlq5TWM2OD1|LkWgcm0> NUTJNFJPW0GQR1XS
RPMI-8402 NF\pd5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTNwNTDuUS=> NYD2PYduW0GQR1XS
KARPAS-45 M2jDOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7HWFdKSzVyPUOuOVQhdk1? MYXTRW5ITVJ?
HCC1187 NYHj[WZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzId5JKSzVyPUOuOVQhdk1? M2j2fHNCVkeHUh?=
MZ1-PC NWLpV2p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLDWIRKSzVyPUOuOVQhdk1? M1\VTHNCVkeHUh?=
no-11 NFfi[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwNUWgcm0> M3vvbnNCVkeHUh?=
EVSA-T NYTmZVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrmbJg4UUN3ME2zMlYhdk1? MWHTRW5ITVJ?
DJM-1 NWDr[|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTNwNkOgcm0> MonqV2FPT0WU
COLO-684 MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjQTWM2OD1|Lk[2JI5O MWrTRW5ITVJ?
NMC-G1 M160Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPlTWM2OD1|Lk[4JI5O MoDnV2FPT0WU
LC-1F M{jERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr5eoR5UUN3ME2zMlc1KG6P M3WzNHNCVkeHUh?=
RL95-2 M1HpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIX0T5hKSzVyPUOuO|khdk1? Mmm4V2FPT0WU
COLO-320-HSR MmPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXRTFk2UUN3ME2zMlkzKG6P NGjvbnBUSU6JRWK=
RCC10RGB Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLmVG1mUUN3ME2zMlk{KG6P NVezNmxoW0GQR1XS
HD-MY-Z MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTNwOUOgcm0> NHjUVlVUSU6JRWK=
NCI-H2141 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;1VWlEPTB;ND6wOUBvVQ>? MYPTRW5ITVJ?
K-562 M17zPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjC[|ZKSzVyPUSuNVIhdk1? NWHPPYM2W0GQR1XS
NCI-H1648 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkH5TWM2OD12LkGzJI5O M3PyVnNCVkeHUh?=
OMC-1 NV7sOZVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L0dGlEPTB;ND6xPEBvVQ>? NGnENZNUSU6JRWK=
LB647-SCLC M4P3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZZmlEPTB;ND6yNkBvVQ>? M1fwWXNCVkeHUh?=
TE-12 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTRwMkWgcm0> MUPTRW5ITVJ?
NOMO-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC1bIcyUUN3ME20MlM{KG6P NF70ZmpUSU6JRWK=
Raji M1\zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H2SGlEPTB;ND60OkBvVQ>? MX7TRW5ITVJ?
NALM-6 NGXVfG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwNEmgcm0> Mlv4V2FPT0WU
HL-60 M3eyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqwVJlKSzVyPUSuOlchdk1? M3LlSnNCVkeHUh?=
IST-SL1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHKPIdKSzVyPUSuOlghdk1? M2WxOHNCVkeHUh?=
MHH-PREB-1 M1\TO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTRwOE[gcm0> NFfEbm5USU6JRWK=
MHH-NB-11 M1zFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17q[2lEPTB;ND65NUBvVQ>? MlzKV2FPT0WU
JiyoyeP-2003 NGi5UWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTVibl2= M3nQ[XNCVkeHUh?=
SBC-1 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTVwMEGgcm0> MmLlV2FPT0WU
CHP-126 NUL0PINST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\PSYVKSzVyPUWuNFYhdk1? M{i2O3NCVkeHUh?=
LU-139 NYPiXVVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVO2TYNRUUN3ME21MlE{KG6P MUfTRW5ITVJ?
NCI-SNU-5 NXLBbXJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof0TWM2OD13LkG3JI5O MnLCV2FPT0WU
SW962 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HDZWlEPTB;NT6yNUBvVQ>? MYPTRW5ITVJ?
EW-1 NEW4V|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTVwM{Ggcm0> M{DhenNCVkeHUh?=
NCI-H1417 M2f1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPyTWM2OD13LkWxJI5O NVviPWt2W0GQR1XS
LU-65 NGLCToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[wTWM2OD13Lki0JI5O MYPTRW5ITVJ?
D-502MG NVTiXm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPid4JnUUN3ME22MlM4KG6P MlTWV2FPT0WU
BC-3 MkfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX20ZmtGUUN3ME22MlYyKG6P M2\adXNCVkeHUh?=
GDM-1 MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTZwN{egcm0> M4D1NHNCVkeHUh?=
NCI-H2196 NXzVW|lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjpTWM2OD14Lkigcm0> MXLTRW5ITVJ?
NB1 M3LZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TSUmlEPTB;Nj64PEBvVQ>? NHfzN4ZUSU6JRWK=
NCI-H345 NGjDSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPmeIdKSzVyPUeuNkBvVQ>? M1jS[HNCVkeHUh?=
SU-DHL-1 NYDrbGNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoC0TWM2OD15LkK0JI5O MlvFV2FPT0WU
JVM-2 NGficmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTdwMkigcm0> NVXSfG1qW0GQR1XS
LU-134-A NYfvdFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmOGVKSzVyPUeuN|khdk1? Mn\hV2FPT0WU
NCI-H1694 Mn;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnuNWZPUUN3ME23MlU5KG6P M1fvc3NCVkeHUh?=
NCI-SNU-16 MlnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrKPYJbUUN3ME23MlY2KG6P MYTTRW5ITVJ?
L-363 NX\LOIQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PJRmlEPTB;Nz63JI5O M{jvZXNCVkeHUh?=
KG-1 M2LaT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHze5ZKSzVyPUeuPVQhdk1? M2DSUXNCVkeHUh?=
MN-60 NI\LTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRThwMUSgcm0> MljvV2FPT0WU
NB6 NFnjT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXDTWM2OD16LkS4JI5O MWLTRW5ITVJ?
MLMA NUWwO3JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYK1VVhGUUN3ME24Mlg2KG6P MlPqV2FPT0WU
ATN-1 MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzP[4JMUUN3ME24Mlg6KG6P MlK0V2FPT0WU
SK-NEP-1 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTlwMEGgcm0> NXrDO3BlW0GQR1XS
DMS-114 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYSyXpZGUUN3ME25MlYzKG6P NXu0VVRjW0GQR1XS
CTB-1 NFXUNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojPTWM2OD17Lk[3JI5O M1HCS3NCVkeHUh?=
NCI-H2081 NIXCWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW4eWZTUUN3ME2xNE4xQSCwTR?= MnnBV2FPT0WU
ES5 M17O[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\RUZd2UUN3ME2xNE4{QCCwTR?= NH3HXHpUSU6JRWK=
HCC1599 NXTXR3I4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFGwNIFKSzVyPUGxMlkyKG6P MWXTRW5ITVJ?
NCI-H23 NHHaXVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrxSWVKSzVyPUGyMlEzKG6P NWrhbIViW0GQR1XS
NCI-H1581 MlzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTFTWM2OD1zMj6yPEBvVQ>? NVe1S5JwW0GQR1XS
JVM-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\sWmlEPTB;MUKuPVkhdk1? MVfTRW5ITVJ?
NCI-SNU-1 NFXlbotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTF|LkG5JI5O M4jE[3NCVkeHUh?=
NB7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF3LkmyJI5O NYPVZVhwW0GQR1XS
JAR NH3KUFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf2WmpKSzVyPUG2MlE{KG6P MVvTRW5ITVJ?
TGW M{S0Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfSTWM2OD1zNj60PEBvVQ>? MYDTRW5ITVJ?
U-87-MG MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXneo1PUUN3ME2xOk44PiCwTR?= NFL3WGFUSU6JRWK=
NCI-H1436 NEPZUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrrXGdZUUN3ME2xO{4xOSCwTR?= MYrTRW5ITVJ?
GOTO NEKwcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF5LkC2JI5O NFjzfYRUSU6JRWK=
COLO-800 NFXBWY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[1VGpKSzVyPUG3MlY1KG6P M3PCd3NCVkeHUh?=
MFM-223 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTncFdvUUN3ME2xO{46OSCwTR?= MUTTRW5ITVJ?
EW-18 NGnpdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrETWM2OD1zNz65OkBvVQ>? Ml7vV2FPT0WU
NB14 MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjsTWM2OD1zNz65PEBvVQ>? M1f0eXNCVkeHUh?=
EB2 NGC1SG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDqc49wUUN3ME2xPE4xQCCwTR?= NHLJO21USU6JRWK=
EoL-1- NXfwOXh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n0fWlEPTB;MUiuN|Ehdk1? M2LjZ3NCVkeHUh?=
NCCIT MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPwTWM2OD1zOD6zOkBvVQ>? MXfTRW5ITVJ?
DG-75 NH30d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HBRmlEPTB;MUiuOlEhdk1? NEn1dHRUSU6JRWK=
HCC2218 MmLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PUNmlEPTB;MUmuOUBvVQ>? MYXTRW5ITVJ?
TE-6 M1rPWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzjTWM2OD1{MD6wPEBvVQ>? NHj2SZlUSU6JRWK=
SF539 M{GzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEi4NnRKSzVyPUKwMlY4KG6P M4m5RnNCVkeHUh?=
NCI-H446 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DMVGlEPTB;MkGuNVghdk1? NFPQZo5USU6JRWK=
IST-MES1 NIG4VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\sSopGUUN3ME2yNk44PyCwTR?= NWTR[Ww6W0GQR1XS
NCI-H82 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm0R3VnUUN3ME2yN{4xOiCwTR?= MnnuV2FPT0WU
HCC2157 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi0c5kzUUN3ME2yN{4yOyCwTR?= MoCyV2FPT0WU
EW-12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD1{Mz6xO{BvVQ>? MVvTRW5ITVJ?
SIMA M3:3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnoTlJNUUN3ME2yN{4{QCCwTR?= MXfTRW5ITVJ?
DOHH-2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDW[pZKSzVyPUKzMlQ2KG6P NFm5cJNUSU6JRWK=
IM-9 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XTRmlEPTB;MkOuOVQhdk1? NUDQOI06W0GQR1XS
EC-GI-10 NVPFdJhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37hdGlEPTB;MkSuNlMhdk1? M2DWVXNCVkeHUh?=
HDLM-2 NWC3NlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTHTWM2OD1{ND61OEBvVQ>? NEPCXpNUSU6JRWK=
LS-1034 NVq4XXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTK[FVyUUN3ME2yOU44PSCwTR?= Moe1V2FPT0WU
REH NYrUWHdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ4LkSxJI5O M3zzTnNCVkeHUh?=
LU-165 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnxVWFTUUN3ME2yOk44OiCwTR?= NVrtSoFrW0GQR1XS
NH-12 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXsTWM2OD1{Nz62O{BvVQ>? NVXlZ4NFW0GQR1XS
WSU-NHL MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfwNpVKSzVyPUK4MlM6KG6P NHX6O|JUSU6JRWK=
ECC4 NYi1fINlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXGTWM2OD1{OD63PUBvVQ>? NUDoNo1QW0GQR1XS
OCI-AML2 M2\SO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ7Lk[5JI5O M{XzdXNCVkeHUh?=
EW-3 M{S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNyLkW5JI5O M1vQeHNCVkeHUh?=
NCI-H526 MkfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrVTWM2OD1|Mj61OEBvVQ>? Ml7oV2FPT0WU
NCI-H719 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLoT|d2UUN3ME2zOE4{OSCwTR?= MlnRV2FPT0WU
KARPAS-422 MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33wUGlEPTB;M{WuNFQhdk1? NHHPcYFUSU6JRWK=
SK-MEL-1 NXn0cXVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ieI1tUUN3ME2zOU4yPyCwTR?= MkniV2FPT0WU
ES3 NWXNXXFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPrTWM2OD1|NT6xPUBvVQ>? MoqwV2FPT0WU
UACC-812 NHS0eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXXTWM2OD1|NT60OEBvVQ>? MoTiV2FPT0WU
C8166 NHPxWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vReGlEPTB;M{WuO{BvVQ>? M3;oUXNCVkeHUh?=
MDA-MB-134-VI MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3TWM2OD1|NT64O{BvVQ>? NUiyR|RrW0GQR1XS
D-283MED NH7NTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHGeIVKSzVyPUO3Mlc6KG6P M1S0S3NCVkeHUh?=
SHP-77 NHGzXphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pU|dKSzVyPUO4MlA{KG6P MlL2V2FPT0WU
NCI-H2227 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{m3emlEPTB;NECuOFkhdk1? MmraV2FPT0WU
SKM-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofrTWM2OD12Mj62N{BvVQ>? M{TXUnNCVkeHUh?=
L-428 M1n6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDx[|Z6UUN3ME20N{45PiCwTR?= MYfTRW5ITVJ?
RPMI-6666 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;CTWM2OD12NT64PUBvVQ>? NWPwWmhCW0GQR1XS
NCI-H716 M{jycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR6LkixJI5O M2jmNXNCVkeHUh?=
DMS-79 NF7zdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTVyLkexJI5O NIP2[YpUSU6JRWK=
RS4-11 NEnJVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP6TWM2OD13MD64PEBvVQ>? NVPTbGRTW0GQR1XS
NCI-H720 NFXRNW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\vTWM2OD13MT6xNUBvVQ>? NFLBeXBUSU6JRWK=
MC-CAR M2jRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;zTmlEPTB;NUGuOVIhdk1? NV;LdYRNW0GQR1XS
TALL-1 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPRWWJ6UUN3ME21N{46OSCwTR?= NXu3dlBtW0GQR1XS
NCI-N87 NELuTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rjWmlEPTB;NUSuNVghdk1? MkHiV2FPT0WU
P30-OHK MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTV2Lk[xJI5O NFvvdY5USU6JRWK=
LP-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTC[YpKSzVyPU[xMlI5KG6P NIO1eI1USU6JRWK=
YT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7ZNVFKSzVyPU[xMlghdk1? MoXoV2FPT0WU
MRK-nu-1 M361cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjRN5lKSzVyPU[xMlgzKG6P M4HnZnNCVkeHUh?=
BT-474 NUTXNWpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHaRXdKSzVyPU[1JI5O NIHqWnVUSU6JRWK=
NCI-H322M Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XwSWlEPTB;Nk[uNVEhdk1? NF3aVHVUSU6JRWK=
NCI-H128 M{DCcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTd2Lke3JI5O Ml\jV2FPT0WU
KMS-12-PE M1rrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\hd5RUUUN3ME23Ok4zPCCwTR?= NVzKc2g2W0GQR1XS
KP-N-YS MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW5WVRHUUN3ME23Ok44PCCwTR?= NEH3SYZUSU6JRWK=
ALL-PO M3uzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPFTWM2OD15Nz62OkBvVQ>? MUHTRW5ITVJ?
EW-13 MmjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;XbGlEPTB;N{euO|Yhdk1? MYnTRW5ITVJ?
EW-11 M3XzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nxNGlEPTB;N{iuOVIhdk1? MlPIV2FPT0WU
SK-N-FI NF;DWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1KwO2lEPTB;OECuNkBvVQ>? M4LRN3NCVkeHUh?=
CAL-148 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3Xt[2lEPTB;OEGuPFQhdk1? MXHTRW5ITVJ?
RL MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrUblZKSzVyPUi2MlA6KG6P M3XKXXNCVkeHUh?=
AM-38 M{DzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTh6LkC4JI5O NEfu[HBUSU6JRWK=
RH-1 M2PVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mly4TWM2OD17OT64OUBvVQ>? MWjTRW5ITVJ?
NCI-H1770 NGHVVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LV[WlEPTB;MUCyMlQ6KG6P MlnUV2FPT0WU
SIG-M5 MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrZTWM2OD1zMEWuNFYhdk1? NX7EUFV2W0GQR1XS
GR-ST MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFzMz6zOEBvVQ>? NU\3Sm9OW0GQR1XS
ST486 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjrcG4{UUN3ME2xNVQvODZibl2= NH7mcodUSU6JRWK=
NCI-H1650 NI\sZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\hTWM2OD1zMUWuNlkhdk1? NXjUS2x5W0GQR1XS
MHH-CALL-2 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWWxemVVUUN3ME2xNVUvPyCwTR?= M4DVeHNCVkeHUh?=
BV-173 NX3hO3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTF{Mj63NUBvVQ>? M1;0VHNCVkeHUh?=
MC116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTF2OD64OUBvVQ>? NH7nfG5USU6JRWK=
NCI-H524 Mo\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD1zNUmuNUBvVQ>? NYHQN45XW0GQR1XS
SCLC-21H M{L6W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r2UGlEPTB;MUW5MlQyKG6P MofHV2FPT0WU
NCI-H1304 M1n4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TkS2lEPTB;MU[5MlIyKG6P NV\r[nJkW0GQR1XS
NCI-H510A NVrmXmV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTF6NT6zO{BvVQ>? NVLsUlF1W0GQR1XS
NCI-H209 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2juNGlEPTB;MUm2MlUzKG6P NF\zWmFUSU6JRWK=
KM-H2 M1;FUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPlTWM2OD1zOUeuNFUhdk1? NI\DdGxUSU6JRWK=
NCI-H1395 NVXlWpFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3sNXZKSzVyPUKxNE4yOyCwTR?= M1LPTnNCVkeHUh?=
NCI-H1155 NFeydIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHFWVMxUUN3ME2yN|AvOzJibl2= NFf6R2VUSU6JRWK=
COR-L279 NEXWOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULsW5dxUUN3ME2yOVIvOTdibl2= NWPLPIt3W0GQR1XS
NCI-H1299 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ruNmlEPTB;Mk[xMlcyKG6P MW\TRW5ITVJ?
EW-22 NUTwfmFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnuT21yUUN3ME2yOlMvPzVibl2= NF\jOGFUSU6JRWK=
SK-MEL-2 M{XtcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DXeGlEPTB;MkixMlkhdk1? NEf2XphUSU6JRWK=
KASUMI-1 NIXuNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\MVGlEPTB;MkizMlA2KG6P MVXTRW5ITVJ?
NCI-H187 NXzoUVJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfvUHpsUUN3ME2yPFcvODhibl2= M3f4dHNCVkeHUh?=
NCI-H2171 MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXFVFZtUUN3ME2yPFgvQTJibl2= Mki4V2FPT0WU
LNCaP-Clone-FGC M{\LTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H0TmlEPTB;Mkm1MlI3KG6P MVrTRW5ITVJ?
NCI-H1522 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTQZm5[UUN3ME2zNFcvODVibl2= M2Ljb3NCVkeHUh?=
SCH MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHHWIRKSzVyPUOyNk4zOiCwTR?= M3jzPHNCVkeHUh?=
THP-1 MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonWTWM2OD1|MkKuOkBvVQ>? M{\BfnNCVkeHUh?=
SNU-C1 M{fRS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHzTWM2OD1|NkKuNFkhdk1? MUnTRW5ITVJ?
CA46 M1K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfhWoNbUUN3ME2zO|MvPjNibl2= NWPDbI9qW0GQR1XS
NCI-H1963 NEjXdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrTcWc1UUN3ME2zPFYvOTlibl2= NWPDcG04W0GQR1XS
DEL MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTHTWM2OD1|OUGuNlchdk1? MUTTRW5ITVJ?
TUR NEnMWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnNTWM2OD1|OU[uOlEhdk1? MXfTRW5ITVJ?
NCI-H226 NH3JS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDV21KSzVyPUSwN{4zOyCwTR?= M13xTnNCVkeHUh?=
COLO-668 MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLFTWM2OD12MEOuOVchdk1? M{XQfHNCVkeHUh?=
CPC-N MlTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjuU3hKSzVyPUSwN{44PyCwTR?= NVLXb3dVW0GQR1XS
NCI-H889 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfnZmdoUUN3ME20OlEvQTJibl2= MVjTRW5ITVJ?
J-RT3-T3-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTV|Mj61O{BvVQ>? M2nWO3NCVkeHUh?=
MSTO-211H NX\EcZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvLR3hjUUN3ME21O|QvOjZibl2= NGDne|BUSU6JRWK=
SCC-15 NFmyZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTZ4Nz60O{BvVQ>? NF;YflNUSU6JRWK=
SUP-T1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDPVoFKSzVyPU[4Ok4xPCCwTR?= M{nqS3NCVkeHUh?=
DMS-153 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnjfG9KSzVyPUe0Ok45OyCwTR?= NVrhNXBsW0GQR1XS
MS-1 NVj4emtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr6V3JKSzVyPUe1PU41OiCwTR?= NUj0NoFkW0GQR1XS
TC-YIK NVfHRmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2NmlEPTB;N{ixMlAyKG6P M3HDdHNCVkeHUh?=
RPMI-8866 M{\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXUfm1yUUN3ME2xNFA3NjJ6IN88US=> MXzTRW5ITVJ?
KY821 NHL0VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHVdG03UUN3ME2xNFM3NjB2IN88US=> Ml;vV2FPT0WU
P31-FUJ MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1zMUGyMlc2KM7:TR?= MX\TRW5ITVJ?
COLO-824 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF{NkGuO|gh|ryP M2TlUXNCVkeHUh?=
U-698-M NULKS2ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJ{NkKuNVUh|ryP NVHieHB[W0GQR1XS
TE-441-T NW[2S4xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;uRmJKUUN3ME2yOVIyNjdizszN M1fXeHNCVkeHUh?=
IMR-5 M{fo[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHMN3hKSzVyPUO0NFkvPjJizszN MkfBV2FPT0WU
NCI-H1838 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTRTWM2OD12MUi2MlMzKM7:TR?= NILicXhUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay:

[4]

+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research:

[5]

+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01891968 Completed Leukemia M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc. August 7, 2013 Phase 2
NCT01445405 Completed Carcinoma, Squamous|Head and Neck Cancer|Oral Cancer|Laryngeal Cancer|Pharyngeal Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 5, 2008 Phase 1
NCT02211755 Recruiting Neoplasms|Myelodysplastic Syndromes National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 30, 2014 Phase 1
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT00011778 Completed Squamous Cell Carcinoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) February 22, 2001 Phase 1
NCT02658396 Withdrawn Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) June 2017 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID